These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9731928)

  • 1. Differences in perceived and presented adverse drug reactions in general practice.
    Ottervanger JP; Valkenburg HA; Grobbee DE; Stricker BH
    J Clin Epidemiol; 1998 Sep; 51(9):795-9. PubMed ID: 9731928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.
    Ottervanger JP; van Witsen TB; Valkenburg HA; Grobbee DE; Stricker BH
    Eur J Clin Pharmacol; 1994; 47(4):305-9. PubMed ID: 7875179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and determinants of sumatriptan-associated chest pain.
    Ottervanger JP; Valkenburg HA; Grobbee DE; Stricker BH
    Arch Neurol; 1997 Nov; 54(11):1387-92. PubMed ID: 9362987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of sumatriptan use and overuse in general practice.
    Ottervanger JP; Valkenburg HA; Grobbee DE; Stricker BH
    Eur J Clin Pharmacol; 1996; 50(5):353-5. PubMed ID: 8839655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
    Wilton LV; Shakir S
    Epilepsia; 2002 Sep; 43(9):983-92. PubMed ID: 12199723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing study of cardiovascular adverse reactions associated with sumatriptan.
    Ottervanger JP; van Witsen TB; Valkenburg HA; Stricker BH
    BMJ; 1993 Nov; 307(6913):1185. PubMed ID: 8251846
    [No Abstract]   [Full Text] [Related]  

  • 9. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme.
    Ranganathan SS; Houghton JE; Davies DP; Routledge PA
    Br J Clin Pharmacol; 2003 Dec; 56(6):658-63. PubMed ID: 14616426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-administration of fluoxetine and sumatriptan: the Canadian experience.
    Joffe RT; Sokolov ST
    Acta Psychiatr Scand; 1997 Jun; 95(6):551-2. PubMed ID: 9242852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN; Wilton LV; Shakir SW
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.
    Diener HC; Evers S
    Clin Drug Investig; 2007; 27(1):59-66. PubMed ID: 17177580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature.
    Ottervanger JP; Wilson JH; Stricker BH
    Eur J Clin Pharmacol; 1997; 53(2):105-10. PubMed ID: 9403280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of pain by sumatriptan.
    Coulter DM; Passier JL; Clark DW; van Puijenbroek EP
    Headache; 2003 Oct; 43(9):994-9. PubMed ID: 14511277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of adverse drug reactions by general practitioners: a questionnaire-based study in the Netherlands.
    Passier A; ten Napel M; van Grootheest K; van Puijenbroek E
    Drug Saf; 2009; 32(10):851-8. PubMed ID: 19722728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
    Cossmann M; Kohnen C; Langford R; McCartney C
    Drugs; 1997; 53 Suppl 2():50-62. PubMed ID: 9190325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under-reporting of adverse drug reactions in general practice.
    Moride Y; Haramburu F; Requejo AA; Bégaud B
    Br J Clin Pharmacol; 1997 Feb; 43(2):177-81. PubMed ID: 9131950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
    Welch KM
    Cephalalgia; 2001; 21 Suppl 1():25-8. PubMed ID: 11678818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.